At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 295 enrolled
Drug / intervention
Pembrolizumab +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1/2 Clinical Trial to Study the Safety and Tolerability of MK-3475 + Pegylated Interferon Alfa-2b (PEG-IFN) and MK-3475 + Ipilimumab (IPI) in Subjects With Advanced Melanoma (MEL) and Renal Cell Carcinoma (RCC) (KEYNOTE 029)
In Brief
A Phase 2 clinical trial evaluating Pembrolizumab, PegIFN-2b, and 1 other intervention for Renal Cell Carcinoma and Melanoma. Completed, enrolled 295 participants.
Detailed Summary
This study is being done to analyze the safety, tolerability, and efficacy of treatment for advanced melanoma (MEL) and renal cell carcinoma (RCC) using combination regimens of pembrolizumab + pegylated interferon alfa-2b (PegIFN-2b) and pembrolizumab + ipilimumab (IPI). The primary hypothesis is that these combinations will be sufficiently well-tolerated to permit continued clinical investigation.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRenal Cell Carcinoma, Melanoma
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartMar 2014
First PostedMar 2014
Primary CompletionApr 2021
TodayJul 2026
First PostedMar 18, 2014
Enrollment StartMar 17, 2014
Primary CompletionApr 1, 2021
TodayJul 2, 2026
Enrollment to primary: 7.0 yearsPosted 12.3 years ago
Interventions
Pembrolizumabbiological
IV infusion
PegIFN-2bbiological
Subcutaneous infusion
Ipilimumabbiological
IV infusion